Aventura Private Wealth’s Royalty Pharma RPRX Stock Holding History

Aventura Private Wealth’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.65K	Buy	+65	New	+$3.38K	﹤0.01%	734

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aventura Private Wealth's RPRX Position: Q2 2026 in Review

Aventura Private Wealth opened a new position in Royalty Pharma (RPRX) in Q2 2026: 65 shares worth $3.65K. The stake represents ﹤0.01% of the portfolio and ranks #734 among its holdings.

641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Aventura Private Wealth held 65 shares of Royalty Pharma worth $3.65K as of Q2 2026.
Royalty Pharma was a new Aventura Private Wealth position in Q2 2026.
Royalty Pharma made up ﹤0.01% of Aventura Private Wealth's portfolio in Q2 2026, its #734 holding.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Aventura Private Wealth's 13F filing for Q2 2026, filed 15 Jul 2026.